To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies. Onno van de Stolpe is the CEO of the company.
Additional recommended knowledge
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Categories: Pharmaceutical companies | Pharmaceutical industry
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Galapagos_Genomics". A list of authors is available in Wikipedia.|